Inovio Pharmaceuticals (MEX:INO) Cyclically Adjusted Book per Share: MXN275.74 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:INO Inovio Pharmaceuticals Inc MEX:INO
40 GF Score
Price MXN11.50
GF Value MXN3.68
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Inovio Pharmaceuticals Cyclically Adjusted Book per Share?

Inovio Pharmaceuticals MEX:INO -36.11% 40 Cyclically Adjusted Book per Share is MXN275.74 as of Mar. 2026. GuruFocus rates MEX:INO with a GF Score™ of 40/100 and a GF Value™ of MXN3.68 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Inovio Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was MXN1.568. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is MXN275.74 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Inovio Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was -17.90% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -9.00% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -2.40% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -2.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Inovio Pharmaceuticals was 4.80% per year. The lowest was -14.30% per year. And the median was -5.50% per year.

As of today (2026-07-31), Inovio Pharmaceuticals's current stock price is MXN11.50. Inovio Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was MXN275.74. Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 0.04.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Inovio Pharmaceuticals was 18.50. The lowest was 0.04. And the median was 1.85.


Inovio Pharmaceuticals  (MEX:INO) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=11.50/275.74
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Inovio Pharmaceuticals was 18.50. The lowest was 0.04. And the median was 1.85.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Inovio Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Inovio Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Inovio Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inovio Pharmaceuticals Cyclically Adjusted Book per Share Chart

Inovio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 433.88 405.94 361.29 426.02 298.78

Inovio Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 420.86 405.84 334.70 298.78 275.74

MEX:INO vs TELO, ELTX, ALPS: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inovio Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


MEX:INO
40GF Score
Inovio Pharmaceuticals Inc MEX:INO
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inovio Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Inovio Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.568/330.2130*330.2130
=1.568

Current CPI (Mar. 2026) = 330.2130.

Inovio Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 489.196 241.018 670.236
201609 460.746 241.428 630.185
201612 411.812 241.432 563.246
201703 320.475 243.801 434.063
201706 344.903 244.955 464.948
201709 390.750 246.819 522.775
201712 371.385 246.524 497.461
201803 271.584 249.554 359.363
201806 287.141 251.989 376.277
201809 246.168 252.439 322.010
201812 210.687 251.233 276.921
201903 185.183 254.202 240.556
201906 125.371 256.143 161.625
201909 80.590 256.759 103.645
201912 7.669 256.974 9.855
202003 355.432 258.115 454.713
202006 324.971 257.797 416.256
202009 512.525 260.280 650.232
202012 589.109 260.474 746.836
202103 681.491 264.877 849.591
202106 578.077 271.696 702.581
202109 532.022 274.310 640.445
202112 452.598 278.802 536.057
202203 374.555 287.504 430.196
202206 290.354 296.311 323.574
202209 258.038 296.808 287.080
202212 205.547 296.797 228.689
202303 164.002 301.836 179.421
202306 129.983 305.109 140.678
202309 107.064 307.789 114.864
202312 87.391 306.746 94.077
202403 67.065 312.332 70.904
202406 68.259 314.175 71.743
202409 55.582 315.301 58.211
202412 39.576 315.605 41.408
202503 28.590 319.799 29.521
202506 14.630 322.561 14.977
202509 -2.643 324.800 -2.687
202512 6.288 324.054 6.408
202603 1.568 330.213 1.568

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of MXN275.74 mean?
Inovio Pharmaceuticals (MEX:INO) has a Cyclically Adjusted Book per Share of MXN275.74 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Inovio Pharmaceuticals and its competitors.
Is Inovio Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Inovio Pharmaceuticals' current Cyclically Adjusted Book per Share is MXN275.74. Overall, Inovio Pharmaceuticals has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inovio Pharmaceuticals' Cyclically Adjusted Book per Share compare to TELO and ELTX?
Inovio Pharmaceuticals' Cyclically Adjusted Book per Share of MXN275.74 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Inovio Pharmaceuticals and its competitors. Inovio Pharmaceuticals's current Cyclically Adjusted Book per Share is MXN275.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inovio Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Inovio Pharmaceuticals (MEX:INO) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN3.68, compared to a current price of MXN11.50 — trading 212.5% above its estimated fair value. The current Cyclically Adjusted Book per Share is MXN275.74. Inovio Pharmaceuticals' overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Inovio Pharmaceuticals (MEX:INO), the current Cyclically Adjusted Book per Share is MXN275.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inovio Pharmaceuticals (MEX:INO) Overvalued in 2026?

Based on GuruFocus' analysis, Inovio Pharmaceuticals stock appears to be overvalued. The current stock price of MXN11.50 is trading 212.5% above its estimated GF Value™ of MXN3.68. GuruFocus considers Inovio Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for MEX:INO:

  • Cyclically Adjusted Book per Share: MXN275.74
  • GF Value™: MXN3.68 vs. price of MXN11.50 (212.5% above fair value)
  • GF Score™: 40/100 with 4 warning signs

No single metric tells the full story. See the MEX:INO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Inovio Pharmaceuticals Business Description

Other Exchanges INO:USA0A43:UKGBM:Germany
Address 660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
40GF Score

Get the complete analysis for MEX:INO

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN11.50
Price
MXN3.68
GF Value